Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.